Cargando…

Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection

INTRODUCTION: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes. PURPOSE: To co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, Jillian Kallman, Gerber, Lynn H, Stepanova, Maria, de Avila, Leyla, Weinstein, Ali A, Pham, Huong, Nader, Fatema, Afendy, Mariam, Terra, Kathy, Austin, Patrick, Keo, Wisna’odom, Racila, Andrei, Estep, James Michael, Gerber, Suzannah, Verma, Manisha, Golabi, Pegah, Lam, Brian P, Younossi, Zobair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145429/ https://www.ncbi.nlm.nih.gov/pubmed/37123886 http://dx.doi.org/10.2147/IJGM.S406571

Ejemplares similares

Severe, Persistent, Disruptive Fatigue Post-SARS-CoV-2 Disproportionately Affects Young Women
por: Price, Jillian Kallman, et al.
Publicado: (2023)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
por: Younossi, Zobair M., et al.
Publicado: (2021)

Exercise as an intervention for patients with end-stage liver disease: Systematic review
por: Locklear, Cameron T., et al.
Publicado: (2018)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
por: Younossi, Zobair M, et al.
Publicado: (2012)

Diet Satisfaction and Adequate Food Intake in Patients with Chronic Liver Diseases
por: Gerber, Suzannah, et al.
Publicado: (2022)

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
por: Weinstein, Ali A, et al.
Publicado: (2022)

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
por: Golabi, Pegah, et al.
Publicado: (2020)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Association of physical activity and fine motor performance in individuals with type 2 diabetes mellitus and/or non-alcoholic fatty liver disease
por: Weinstein, Ali A., et al.
Publicado: (2023)

Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example
por: Page, Sandra, et al.
Publicado: (2013)

Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor
por: Stepanova, Maria, et al.
Publicado: (2016)

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
por: Birerdinc, Aybike, et al.
Publicado: (2012)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19
por: Stepanova, Maria, et al.
Publicado: (2022)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
por: Golabi, Pegah, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
por: Paik, James M., et al.
Publicado: (2019)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices
por: Younossi, Zobair M., et al.
Publicado: (2021)

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
por: Golabi, Pegah, et al.
Publicado: (2020)

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
por: Paik, James M., et al.
Publicado: (2020)

The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007‐2017
por: Paik, James M., et al.
Publicado: (2021)

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
por: Arshad, Tamoore, et al.
Publicado: (2018)

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

Impact of healthcare reform on the payer mix among young adult emergency department utilizers across the United States (2005–2015)
por: Bush, Haley, et al.
Publicado: (2018)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
por: Shahab, Omer, et al.
Publicado: (2019)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
por: Shahab, Omer, et al.
Publicado: (2018)

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
por: Golabi, Pegah, et al.
Publicado: (2017)

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
por: Golabi, Pegah, et al.
Publicado: (2019)

Importance of fatigue and its measurement in chronic liver disease
por: Gerber, Lynn H, et al.
Publicado: (2019)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0u3b777pgic0ieb93albb1ttsq